Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with Major Depressive Disorder

Stefanie Wagner, Isabella Helmreich, Daniel Wollschläger, Konstantin Meyer, Sabine Kaaden, Julia Reiff, Sibylle C Roll, Dieter Braus, Oliver Tüscher, Florian Müller-Dahlhaus, André Tadić, Klaus Lieb, Stefanie Wagner, Isabella Helmreich, Daniel Wollschläger, Konstantin Meyer, Sabine Kaaden, Julia Reiff, Sibylle C Roll, Dieter Braus, Oliver Tüscher, Florian Müller-Dahlhaus, André Tadić, Klaus Lieb

Abstract

Executive dysfunctions frequently occur in patients with Major Depressive Disorder and have been shown to improve during effective antidepressant treatment. However, the time course of improvement and its relationship to treatment outcome is unknown. The aim of the study was to assess the test performance and clinical outcome by repetitive assessments of executive test procedures during antidepressant treatment. Executive test performance was assessed in 209 -patients with Major Depressive Disorder (mean age 39.3 ± 11.4 years) and 84 healthy controls five times in biweekly intervals from baseline to week 8. Patients were treated by a defined treatment algorithm within the early medication change study (EMC trial; ClinicalTrials.gov NCT00974155), controls did not receive any intervention. Cognitive domains were processing speed, cognitive flexibility, phonemic and semantic verbal fluency. Intelligence was assessed at baseline. Depression severity was tested once a week by the Hamilton Depression Rating Scale (HAMD17). 130 patients (62%) showed executive dysfunctions in at least one of four tests at baseline. Linear mixed regression models revealed that the course of depression severity was associated to the course of cognitive flexibility (p = 0.004) and semantic verbal fluency (p = 0.020). Cognitive flexibility and semantic verbal fluency may be candidates easily to apply for therapy response prediction in clinical routine, which should be tested in further prospective studies.

Trial registration: ClinicalTrials.gov NCT00974155 EudraCT: 2008-008280-96.

Conflict of interest statement

Competing Interests: All authors have declared that no competing interests exist.

Figures

Fig 1. CONSORT flow chart.
Fig 1. CONSORT flow chart.
AE: adverse events.
Fig 2. Course of executive test performance…
Fig 2. Course of executive test performance in patients (N = 209) and controls (N = 84).
TMT: Trail Making Test; PR: percentiles; * p

Fig 3. TMT test performance in patients…

Fig 3. TMT test performance in patients with no cognitive impairment (“not impaired”) and in…

Fig 3. TMT test performance in patients with no cognitive impairment (“not impaired”) and in patients with cognitive impairment at baseline which normalized (“normalized”) or did not normalize (“impaired”) at endpoint.
TMT: Trail Making Test.
Fig 3. TMT test performance in patients…
Fig 3. TMT test performance in patients with no cognitive impairment (“not impaired”) and in patients with cognitive impairment at baseline which normalized (“normalized”) or did not normalize (“impaired”) at endpoint.
TMT: Trail Making Test.

References

    1. Snyder HR. Major Depressive Disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psych Bulletin. 2013;139: 81–132.
    1. Bortolato B, Carvalho AF, McIntyre RS. Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. CNS Neurol Disord Drug Targets. 2014;13: 1804–1818.
    1. Wagner S, Doering B, Helmreich I, Lieb K, Tadic A. A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand. 2011a;125: 281–292.
    1. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, et al. Regional metabolic effects of Fluoxetine in Major Depression: Serial changes and relationship to clinical response. Biol Psychiatry. 2000;48: 830–843.
    1. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bulletin. 2003;65: 193–207.
    1. Neu P, Bajbouj M, Schilling A, Godemann F, Berman RM, Schlattmann P. Cognitive function over the treatment course of depression in middle-aged patients: correlation with brain MRI signal hyper intensities. J Psychiatr Res. 2005;39: 129–135. doi:
    1. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major Depressive Disorder: A systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol. 2015;19: 1–13.
    1. Nakano Y, Baba H, Maeshima H, Kitajima A, Sakai Y, Baba K, et al. Executive dysfunction in medicated, remitted state of major depression. J Affect Dis. 2011;111: 46–51.
    1. Reppermund S, Zihl J, Lucae S, Horstmann S, Kloiber S, Holsboer F, et al. Persistent Cognitive Impairment in Depression: The Role of Psychopathology and Altered Hypothalamic-Pictuitary-Adrenocortical (HPA) System Regulation. Biol Psychiatry. 2007;62: 400–406. doi:
    1. Reppermund S, Ising M, Lucae S, Zihl J. Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis. Psychol Med. 2009;29: 603–614.
    1. Hammar Å, Sørensen L, Årdal G, Oedegaard J, Kroken R, Roness A, et al. Enduring cognitive dysfunction in unipolar major depression: A test-retest study using the Stroop paradigm. Sc J Psychology. 2010;51: 304–308.
    1. Hinkelmann K, Moritz S, Botzenhardt J, Muhtz C, Wiedemann K, Kellner M, et al. Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: A longitudinal study. Psychoneuroendocrinology. 2012;37: 685–692. doi:
    1. Beblo T, Baumann B, Bogerts B, Wallesch CW, Herrmann M. Neuropsychological Correlates of Major Depression: A Short-term Follow-up. Cogn Neuropsychiatry. 1999;4: 333–341.
    1. Herrera-Guzmán I, Herrera-Abarca JE, Gudayol-Ferré E, Herrera-Guzmán D, Gómez-Carbajal L, Peña-Olvira M, et al. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psych Research. 2010;177: 323–329.
    1. Hausknecht JP, Halpert JA, Di Paolo T, Moriarty Gerrard MO. Retesting in selection: A meta-analysis of coaching and practice effects for test of cognitive ability. J Appl Psychol. 2007;92: 373–385. doi:
    1. Tadić A, Wagner S, Gorbulev S, Dahmen N, Hiemke C, Braus DF, et al. Repetitive measures of peripheral blood and neuropsychological parameters for the identification of early markers of treatment response in patients with Major Depressive Disorder. BMC Psychiatry. 2011;11: 16.
    1. Tadić A, Gorbulev S, Dahmen N, Hiemke C, Braus DF, Röschke J, et al. Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder-the EMC trial. Trials. 2010;11: 21 doi:
    1. Nicod N, Wagner S, Vonberg F, Bhomra A, Schlicht KF, Tadic A, et al. The amount of mitochondrial DNA reflects the course of a depressive episode. Biol Psychiatry. 2016;26: 165–72.
    1. Tadić A, Wachtlin D, Berger M, Braus DF, van Calker D, Dahmen N, et al. Randomized Controlled Study of Early Medication Change for Non-Improvers to Antidepressant Therapy in Major Depression—The EMC Trial. Europ Neuropsychopharmacol. 2016;4: 705–716.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed Washington DC: American Psychiatric Press; 2004.
    1. Ackenheil M, Stotz G, Dietz-Bauer R Vossen A. M.I.N.I: International Neuropsychiatric Interview—German Version 5.0.0. Deutschland: München; 1998.
    1. Wittchen HU, Zaudig M, Fydrich T. SKID-I/-II: Strukturiertes klinisches Interview für DSM-IV. Göttingen: Hogrefe; 1996.
    1. Linn B., Linn MW, Gurel L. Cumulative Illness Rating Scale. J. Am. Geriatr. Soc. 2004;16: 622–626.
    1. CIPS (Ed). Internationale Skalen für Psychiatrie. Weinheim: Beltz Test, 1977.
    1. Wagner S, Helmreich I, Lieb K, Tadic A. Standardized rater training for the Hamilton Depression Scale (HAMD17) and the Inventory of Depressive Symptoms (IDS30CR). Psychopathology. 2011b;44: 68–70.
    1. Reitan RM. Trail Making Test—Manual for Administration and Scoring. Tucson: Reitan Neuropsychology Laboratory; 1979.
    1. Aschenbrenner S, Tucha O, Lange KW. RWT Regensburger Wortflüssigkeits-Test. Göttingen: Hogrefe; 2000.
    1. Wagner S, Helmreich I, Dahmen N, Lieb K, Tadic A. Reliability of three alternate forms of the Trail Making Tests A and B. Arch Clin Neuropsychol. 2011c;26: 314–321.
    1. Gaudino EA, Geisler MW, Squires NK. Construct validity in the Trail Making Test: what makes part B harder? J Clin Exp Neuropsychology. 1995;17: 529–535.
    1. Lamberty GJ, Putnam SH, Chatel DM, Bieliauskas LA, Adams KM. Derived Trail Making Test Indices. Neuropsychiatry Neuropsychol Behav Neuro. 1994;7: 230–234.
    1. Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B). Erlangen: Perimed Fachbuch Verlagsgesellschaft mbH; 1969
    1. Tombaugh TN. Trail Making Tests A and B: Normative data stratified by age and education. Arch Clin Neuropsychology. 2003;8: 1–12.
    1. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychology. 1999;14: 167–177.
    1. Kenward MG, Roger JH. Small Sample Inference for Fixed Effects from Restricted Maximum Likelihood. Biometrics 1997; 53: 983–997.
    1. Nakagawa S, Schielzeth H. A general and simple method for obtaining R^2 from Generalized Linear Mixed-effects Models. Methods in Ecology and Evolution 2013; 4: 133–142.
    1. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria: 2017. .
    1. Bates D, Maechler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software 2015; 67: 1–48. doi:
    1. Halekoh U, Højsgaard S. A Kenward-Roger Approximation and Parametric Bootstrap Methods for Tests in Linear Mixed Models—The R Package pbkrtest. Journal of Statistical Software 2014; 58: 1–30.
    1. Christensen H, Griffiths K, MacKinnon A, Jacomb P. A quantitative review of cognitive deficits in depression and Alzheimer-type dementia. J Int. Neuropsychological Society. 1992;3:631–651.
    1. Beblo T, Baune BT. Specifying the neuropsychology of affective disorders: clinical, demographic and neurobioligical factors. Neuropsychol. Rev. 2011; 21:337–359. doi:
    1. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement as a predictor of treatment outcome in patients with major depressive disorder: Why the first 2 weeks really matter-evidence from 6,562 patients. J Clin Psychiatry. 2009;70: 344–353.
    1. Leuchter AF, Cook IA, Hunter AM, Korb AS. A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci. 2009;11: 435–446.
    1. Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry. 2007;68: 1195–1205.
    1. Shilyansky C, Williams LM, Gyurak A, Harris A, Usherwood T, Etkin A. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. Lancet Psychiatry. 2016; 3:425–35.
    1. Thomas AJ, Gallagher P, Robinson LJ, Porter RJ, Young AH, Ferrier IN. A comparison of neurocognitive impairment in younger and older adults with major depression. Psychol Med. 2009;39: 725–733. doi:
    1. Henry J, Crawford JR. A meta-analytic review of verbal fluency deficits in depression. J Clin Exp Neuropsychol. 2005;27: 78–101. doi:
    1. Pachet AK, Wisniewski AM. The effects of lithium on cognition: an update review. Psychopharmacology. 2003;170: 225–234. doi:
    1. Snyder HR, Miyake A, Hankin BL. Advancing understanding of executive function impairments and psychopathology: bridging the gap between clinical and cognitive approaches. Front Psychol. 2015;6: 328–351. doi:

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren